NCI-Designated Cancer Centers Hiking Private Payer Prices for Common Therapies, Study Finds
Substantial and sometimes “excessive” price markups are common among the fraction of National Cancer Institute (NCI)-designated cancer centers that publicly disclosed payer-specific prices for often-used cancer therapies, according to a study published Monday in JAMA Internal Medicine.
